Cargando…

Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease

BACKGROUND: Clinical diagnosis of Alzheimer disease (AD) is only 70% accurate. Reduced cerebral blood flow (CBF) and metabolism in parieto‐temporal and posterior cingulate cortex may assist diagnosis. While widely accepted that (18)F‐fluoro‐2‐deoxyglucose positron emission tomography ( (18)F‐FDG PET...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadebaum, David P., Krishnadas, Natasha, Poon, Aurora M. T., Kalff, Victor, Lichtenstein, Meir, Villemagne, Victor L., Jones, Gareth, Rowe, Christopher C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457212/
https://www.ncbi.nlm.nih.gov/pubmed/32388925
http://dx.doi.org/10.1111/imj.14890
_version_ 1784571039362056192
author Nadebaum, David P.
Krishnadas, Natasha
Poon, Aurora M. T.
Kalff, Victor
Lichtenstein, Meir
Villemagne, Victor L.
Jones, Gareth
Rowe, Christopher C.
author_facet Nadebaum, David P.
Krishnadas, Natasha
Poon, Aurora M. T.
Kalff, Victor
Lichtenstein, Meir
Villemagne, Victor L.
Jones, Gareth
Rowe, Christopher C.
author_sort Nadebaum, David P.
collection PubMed
description BACKGROUND: Clinical diagnosis of Alzheimer disease (AD) is only 70% accurate. Reduced cerebral blood flow (CBF) and metabolism in parieto‐temporal and posterior cingulate cortex may assist diagnosis. While widely accepted that (18)F‐fluoro‐2‐deoxyglucose positron emission tomography ( (18)F‐FDG PET) has superior accuracy to CBF‐SPECT for AD, there are very limited head‐to‐head data from clinically relevant populations and these studies relied on clinical diagnosis as the reference standard. AIMS: To compare directly the accuracy of CBF‐SPECT and (18)F‐FDG PET in patients referred for diagnostic studies in detecting β‐amyloid PET confirmed AD. METHODS: A total of 126 patients, 56% with mild cognitive impairment and 44% with dementia, completed both CBF‐SPECT and (18)F‐FDG PET as part of their diagnostic assessment, and subsequently underwent β‐amyloid PET for research purposes. Transaxial slices and Neurostat 3D‐SSP analyses of (18)F‐FDG PET and CBF‐SPECT scans were independently reviewed by five nuclear medicine clinicians blinded to all other data. Operators selected the most likely diagnosis and their diagnostic confidence. Accuracy analysis used final diagnosis incorporating β‐amyloid PET as the reference standard. RESULTS: Clinicians reported high diagnostic confidence in 83% of (18)F‐FDG PET compared to 67% for CBF‐SPECT (P = 0.001). All reviewers showed individually higher accuracy using (18)F‐FDG PET. Based on majority read, the combined area under the receiver operating characteristic curve in diagnosing AD was 0.71 for (18)F‐FDG PET and 0.61 for CBF‐SPECT (P = 0.02). The sensitivity of (18)F‐FDG PET and CBF‐SPECT was 76% versus 43% (P < 0.001), while specificity was 74% versus 83% (P = 0.45). CONCLUSIONS: (18)F‐FDG PET is superior to CBF‐SPECT in detecting AD among patients referred for the assessment of cognitive impairment.
format Online
Article
Text
id pubmed-8457212
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-84572122021-09-28 Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease Nadebaum, David P. Krishnadas, Natasha Poon, Aurora M. T. Kalff, Victor Lichtenstein, Meir Villemagne, Victor L. Jones, Gareth Rowe, Christopher C. Intern Med J Original Articles BACKGROUND: Clinical diagnosis of Alzheimer disease (AD) is only 70% accurate. Reduced cerebral blood flow (CBF) and metabolism in parieto‐temporal and posterior cingulate cortex may assist diagnosis. While widely accepted that (18)F‐fluoro‐2‐deoxyglucose positron emission tomography ( (18)F‐FDG PET) has superior accuracy to CBF‐SPECT for AD, there are very limited head‐to‐head data from clinically relevant populations and these studies relied on clinical diagnosis as the reference standard. AIMS: To compare directly the accuracy of CBF‐SPECT and (18)F‐FDG PET in patients referred for diagnostic studies in detecting β‐amyloid PET confirmed AD. METHODS: A total of 126 patients, 56% with mild cognitive impairment and 44% with dementia, completed both CBF‐SPECT and (18)F‐FDG PET as part of their diagnostic assessment, and subsequently underwent β‐amyloid PET for research purposes. Transaxial slices and Neurostat 3D‐SSP analyses of (18)F‐FDG PET and CBF‐SPECT scans were independently reviewed by five nuclear medicine clinicians blinded to all other data. Operators selected the most likely diagnosis and their diagnostic confidence. Accuracy analysis used final diagnosis incorporating β‐amyloid PET as the reference standard. RESULTS: Clinicians reported high diagnostic confidence in 83% of (18)F‐FDG PET compared to 67% for CBF‐SPECT (P = 0.001). All reviewers showed individually higher accuracy using (18)F‐FDG PET. Based on majority read, the combined area under the receiver operating characteristic curve in diagnosing AD was 0.71 for (18)F‐FDG PET and 0.61 for CBF‐SPECT (P = 0.02). The sensitivity of (18)F‐FDG PET and CBF‐SPECT was 76% versus 43% (P < 0.001), while specificity was 74% versus 83% (P = 0.45). CONCLUSIONS: (18)F‐FDG PET is superior to CBF‐SPECT in detecting AD among patients referred for the assessment of cognitive impairment. John Wiley & Sons Australia, Ltd 2021-08-22 2021-08 /pmc/articles/PMC8457212/ /pubmed/32388925 http://dx.doi.org/10.1111/imj.14890 Text en © 2020 The Authors. Internal Medicine Journal by Wiley Publishing Asia Pty Ltd on behalf of Royal Australasian College of Physicians. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Nadebaum, David P.
Krishnadas, Natasha
Poon, Aurora M. T.
Kalff, Victor
Lichtenstein, Meir
Villemagne, Victor L.
Jones, Gareth
Rowe, Christopher C.
Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease
title Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease
title_full Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease
title_fullStr Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease
title_full_unstemmed Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease
title_short Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease
title_sort head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and (18)f‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of alzheimer disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457212/
https://www.ncbi.nlm.nih.gov/pubmed/32388925
http://dx.doi.org/10.1111/imj.14890
work_keys_str_mv AT nadebaumdavidp headtoheadcomparisonofcerebralbloodflowsinglephotonemissioncomputedtomographyand18ffluoro2deoxyglucosepositronemissiontomographyinthediagnosisofalzheimerdisease
AT krishnadasnatasha headtoheadcomparisonofcerebralbloodflowsinglephotonemissioncomputedtomographyand18ffluoro2deoxyglucosepositronemissiontomographyinthediagnosisofalzheimerdisease
AT poonauroramt headtoheadcomparisonofcerebralbloodflowsinglephotonemissioncomputedtomographyand18ffluoro2deoxyglucosepositronemissiontomographyinthediagnosisofalzheimerdisease
AT kalffvictor headtoheadcomparisonofcerebralbloodflowsinglephotonemissioncomputedtomographyand18ffluoro2deoxyglucosepositronemissiontomographyinthediagnosisofalzheimerdisease
AT lichtensteinmeir headtoheadcomparisonofcerebralbloodflowsinglephotonemissioncomputedtomographyand18ffluoro2deoxyglucosepositronemissiontomographyinthediagnosisofalzheimerdisease
AT villemagnevictorl headtoheadcomparisonofcerebralbloodflowsinglephotonemissioncomputedtomographyand18ffluoro2deoxyglucosepositronemissiontomographyinthediagnosisofalzheimerdisease
AT jonesgareth headtoheadcomparisonofcerebralbloodflowsinglephotonemissioncomputedtomographyand18ffluoro2deoxyglucosepositronemissiontomographyinthediagnosisofalzheimerdisease
AT rowechristopherc headtoheadcomparisonofcerebralbloodflowsinglephotonemissioncomputedtomographyand18ffluoro2deoxyglucosepositronemissiontomographyinthediagnosisofalzheimerdisease